Last reviewed 2026-04-20 · How we verify

TRIFAROTENE

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Application site irritation
• Sunburn
• Application site pruritus
• Erythema
• Scaling
• Dryness
• Application site pain
• Application site dryness
• Application site discoloration
• Application site rash
• Application site swelling
• Application site erosion

Key clinical trials

• A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris (PHASE3)
• A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris (PHASE1)
• Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris (PHASE3)
• Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation (PHASE4)
• AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation (PHASE4)
• A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris (PHASE1)
• A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis (PHASE2)
• A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TRIFAROTENE CI brief — competitive landscape report
• TRIFAROTENE updates RSS · CI watch RSS